Payment overview · 2025
General Payments
$4,015.22
177 reported records · 30 companies
Healthcare provider profile · identity verified
Gerard J Mcnulty, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TULSA, OK · NPI 1073592945
Verified facts
What the public records show
CMS Open Payments records show Gerard J Mcnulty, M.D. received $4,015.22 in general payments during 2025 across 177 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $640.22 | 15.9% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $491.59 | 12.2% | 29 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $303.61 | 7.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $286.93 | 7.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $280.12 | 7.0% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $249.83 | 6.2% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.28 | 5.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $214.48 | 5.3% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $191.90 | 4.8% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $168.39 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $160.69 | 4.0% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $144.86 | 3.6% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.11 | 2.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.06 | 2.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.00 | 1.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.73 | 1.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.01 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.83 | 1.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $33.97 | 0.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.09 | 0.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.42 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.56 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.73 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.19 | 0.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.24 | 0.6% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $21.10 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.57 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.36 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.13 | 0.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16.22 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,015.22 | 177 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $529.95 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $371.30 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $303.61 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $230.77 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $218.09 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $191.90 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $171.91 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $168.39 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $160.69 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $156.00 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $131.70 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $107.79 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.69 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.69 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.11 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.06 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.58 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.19 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $56.62 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $54.95 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.14 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.73 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $41.83 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $25.88 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 283 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 226 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 185 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
185 | 33 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
226 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
283 | 47 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 222 |
| Levothyroxine Sodium | Levothyroxine Sodium | 615 | 137 |
| Omeprazole | Omeprazole | 598 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 549 | 158 |
| Losartan Potassium | Losartan Potassium | 488 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 452 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 439 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 129 |
| Gabapentin | Gabapentin | 391 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 366 | 61 |
| Meloxicam | Meloxicam | 354 | 100 |
| Potassium Chloride | Potassium Chloride | 323 | 81 |
| Metformin Hcl | Metformin Hcl | 315 | 87 |
| Tramadol Hcl | Tramadol Hcl | 305 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 294 | 60 |
| Eliquis | Apixaban | 283 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 277 | 73 |
| Trazodone Hcl | Trazodone Hcl | 263 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 63 |
| Alprazolam | Alprazolam | 234 | 47 |
| Ozempic | Semaglutide | 226 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 212 | 67 |
| Furosemide | Furosemide | 211 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 45 |
| Donepezil Hcl | Donepezil Hcl | 194 | 48 |
| Prednisone | Prednisone | 192 | 116 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 185 | 33 |
| Valsartan | Valsartan | 181 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 43 |
| Celecoxib | Celecoxib | 177 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 38 |
| Jardiance | Empagliflozin | 164 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 43 |
| Ibandronate Sodium | Ibandronate Sodium | 152 | 52 |
| Famotidine | Famotidine | 147 | 42 |
| Ezetimibe | Ezetimibe | 145 | 42 |
| Memantine Hcl | Memantine Hcl | 140 | 25 |
| Simvastatin | Simvastatin | 138 | 33 |
| Pregabalin | Pregabalin | 136 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 43 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 130 | 28 |
| Lorazepam | Lorazepam | 127 | 37 |
| Mirtazapine | Mirtazapine | 126 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 34 |
| Carvedilol | Carvedilol | 116 | 33 |
| Finasteride | Finasteride | 112 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 105 | 83 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 18 |
| Methylprednisolone | Methylprednisolone | 99 | 82 |
| Temazepam | Temazepam | 97 | 13 |
| Azithromycin | Azithromycin | 96 | 81 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 14 |
| Trulicity | Dulaglutide | 76 | suppressed |
| Synthroid | Levothyroxine Sodium | 75 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 57 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Allopurinol | Allopurinol | 65 | 20 |
| Irbesartan | Irbesartan | 65 | 18 |
| Levofloxacin | Levofloxacin | 64 | 48 |
| Lisinopril | Lisinopril | 63 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Estradiol | Estradiol | 61 | 25 |
| Xarelto | Rivaroxaban | 61 | 17 |
| Morphine Sulfate | Morphine Sulfate | 59 | suppressed |
| Rybelsus | Semaglutide | 59 | 12 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 54 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Trospium Chloride | Trospium Chloride | 53 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 39 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Diazepam | Diazepam | 46 | 11 |
| Eszopiclone | Eszopiclone | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 15 |
| Mupirocin | Mupirocin | 45 | 39 |
| Fluconazole | Fluconazole | 44 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Glimepiride | Glimepiride | 42 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 16 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | 12 |
| Baclofen | Baclofen | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 17 |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 12 |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,015.22 · 177 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREXONT, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SKYCLARYS, SPRAVATO, Sunosi, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, Yorvipath, ZAVZPRET, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error